ESMO Clinical Practice Guideline interim update on new targeted therapies in the first-line and at relapse of chronic lymphocytic leukaemia
Published online: 3 July 2024 - Annals of Oncology
Eichhorst B, Ghia P, Niemann CU, et al., on behalf of the ESMO Guidelines Committee
- The update covers the approval of time-limited ibrutinib–venetoclax in first line and new data on MRD-driven treatment.
- It also covers the approval of the BTKi zanubrutinib in both treatment-naive and relapsed or refractory CLL.
- Additional evidence on the time-limited combination of venetoclax plus an anti-CD20 antibody in the first line are included.
- Options for later-line treatments based on the type of prior lines of treatment are also included.
- Recommendations are based on available scientific data and the authors’ collective expert opinion.